Search clinical trials for: Flucytosine (5-FC)

Total 7844 results

Tocagen Inc.

Completed

Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

Glioblastoma Multiforme | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Tocagen Inc.

Completed

A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma

Glioblastoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Tocagen Inc.

Terminated

A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511

Astrocytoma | Glioblastoma Multiforme | Gliomas, Malignant

United States
Tocagen Inc.

Completed

Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor

Glioblastoma Multiforme | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Tocagen Inc.

Withdrawn

A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Bladder Cancer
Transgene

Terminated

Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

France, United Kingdom
Transgene

Terminated

Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.

Colorectal Neoplasm | Digestive System Neoplasm

France, Spain, Belgium
Anaeropharma Science, Inc.

Suspended

Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

Neoplasms | Cancer | Tumors

United States
Transgene

Completed

Trial of TG4023 Combined With Flucytosine in Liver Tumors

Hepatocellular Carcinoma

France
Assistance Publique - Hôpitaux de Paris
Transgene

Unknown

Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients (ONCOVIRAC)

Glioblastoma | Brain Cancer

France
Tocagen Inc.

Withdrawn

A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care (Toca7)

Newly Diagnosed High Grade Glioma (HGG)
Themis Bioscience GmbH
Assign Data Management and Biostatistics GmbH; Optimapharm

Withdrawn

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Gastrointestinal Cancer

Germany
Tocagen Inc.

Terminated

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Melanoma | Sarcoma | Lymphoma | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | IDH1 Mutated Solid Tumors | IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)

United States
Tocagen Inc.

Terminated

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (Toca5)

Glioblastoma Multiforme | Anaplastic Astrocytoma

United States, Korea, Republic of, Canada, Israel
Ashish Shah
National Cancer Institute (NCI); Denovo Biopharma LLC

Recruiting

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

High Grade Glioma | Anaplastic Astrocytoma

United States
NRG Oncology
National Cancer Institute (NCI)

Withdrawn

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

Glioblastoma | Anaplastic Astrocytoma | Oligodendroglioma | Supratentorial Glioblastoma
Tasly Tianjin Biopharmaceutical Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
City of Hope Medical Center

Completed

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

Recurrent High Grade Glioma | Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain Tumor | Recurrent Grade III Glioma | Adult Brain Tumor | Recurrent Grade IV Glioma | Adult Anaplastic...

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

Anaplastic Oligoastrocytoma | Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS

Cryptococcal Meningitis

South Africa
Shandong University

Recruiting

FIT Combining FC for Predicting MH and Histology Remission in UC

Ulcerative Colitis | Mucosal Healing | Histology Remission | Fecal Calprotetin | FIT

China
Westat
Children's Bureau - Administration for Children and Families

Completed

Nevada Initiative to Reduce Long-Term Foster Care

In Foster Care | At Risk for Foster
Rabin Medical Center
PulseNmore

Recruiting

The Use of PulseNmore FC Device in Patients Undergoing IVF Treatment A Study to Evaluate the Safety and the Efficacy

Women Undergoing Fertility Treatments

Israel
Biomed Research & Technologies, Inc.

Completed

A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis

Atopic Dermatitis

United States
Hospital Universitari Vall d'Hebron Research Institute

Unknown

Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation.

Lung Transplant Rejection

Spain
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumor | Classic Hodgkin Lymphoma

China
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Terminated

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (FORWARD)

Hemophilia A | Hemophilia B

United States
AdvanceCor GmbH
Procorde GmbH

Completed

Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion (PR-15/01)

Myocardial Infarction | Stroke | Thrombosis | Acute Coronary Syndrome

Germany
AryoGen Pharmed Co.

Completed

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Severe Hemophilia A

Iran, Islamic Republic of
University of British Columbia

Active, not recruiting

Pro-active Fecal Calprotectin Monitoring PROMOTE-UC

Ulcerative Colitis

Canada
Protalix

Completed

Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers

Human Volunteer

Israel
University of Ottawa

Completed

It's Time to Address Fear of Cancer Recurrence in Family Caregivers: Online Version of the Fear Of Recurrence Therapy (FC-FORT)

Cancer | CBT | Caregiver | Fear Cancer

Canada
Inozyme Pharma

Recruiting

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency (ENERGY)

Generalized Arterial Calcification of Infancy | Autosomal Recessive Hypophosphatemic Rickets | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

United States, United Kingdom
Inozyme Pharma

Active, not recruiting

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

Generalized Arterial Calcification of Infancy | Autosomal Recessive Hypophosphatemic Rickets | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

United States, Canada, Germany, France, United Kingdom
Inozyme Pharma
IQVIA Biotech

Active, not recruiting

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

Pseudoxanthoma Elasticum | Generalized Arterial Calcification of Infancy | ATP-Binding Cassette Subfamily C Member 6 Deficiency

United States, United Kingdom
Inhibrx, Inc.

Completed

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency (rhAAT-Fc)

Alpha-1 Antitrypsin Deficiency | AATD

United States, New Zealand, United Kingdom
Zhejiang Hisun Pharmaceutical Co. Ltd.

Unknown

Efficacy and Safety Study of Anbainuo in Chinese Patients With RA/AS in the Real World

Rheumatoid Arthritis | Ankylosing Spondylitis
The Hong Kong Polytechnic University

Not yet recruiting

Flipped Classroom Approach in Continuous Ambulatory Peritoneal Dialysis Training (FCCAPD)

Chronic Kidney Disease

Hong Kong
Catholic University of the Sacred Heart

Completed

Self-expandable, Fully Covered Metal Stents in Biliary Strictures Due to Chronic Pancreatitis

Chronic Pancreatitis | Benign Biliary Strictures
FBD Biologics Limited

Recruiting

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Advanced Solid Tumor | Refractory Non-Hodgkin Lymphoma

Taiwan, United States
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Hemophilia A

United States, France, Italy, Spain, Netherlands, United Kingdom, Ireland, New Zealand, Poland, Australia, Germany, Brazil, Sweden, Canada
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND)

Severe Hemophilia B

United States, Italy, Belgium, Australia, Brazil, Hong Kong, India, Ireland, Japan, South Africa, United Kingdom, Netherlands, Sweden, Canada, Poland, China, France, Germany
NYU Langone Health

Recruiting

Modulating Movement Intention Via Cortical Stimulation

Seizures | Seizure Disorder | Psychogenic Movement Disorder

United States
Bioverativ Therapeutics Inc.

Completed

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Severe Hemophilia A

United States, United Kingdom, Australia
Emory University
Bioverativ Therapeutics Inc.

Completed

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

Hemophilia | Menstrual Flow Excessive

United States
University of Manitoba

Active, not recruiting

Financial Coaching for Adults Living With Acquired Brain Injury

Stroke | Brain Injuries

Canada
Hengenix Biotech Inc

Completed

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects

COVID 19

United States
Pfizer

Terminated

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Melanoma | Soft Tissue Sarcoma | Mycosis Fungoides | Breast Carcinoma | Solid Tumors | Squamous Cell Carcinoma | Human Papillomavirus-Related Malignant Neoplasm | Merkel-cell Carcinoma

United States

Search clinical trials for: Flucytosine (5-FC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations